Time to Second Treatment As a Proxy for Overall Survival in CLL/SLL: Identifying Risk Factors to Help Guide Treatment Selection

Authors :: Bantilan, Kurt S.
Soumerai, Jacob D.
Roeker, Lindsey E.
Mato, Anthony R.
Zelenetz, Andrew D.
Source :: Blood; November 2019, Vol. 134 Issue: 1, Number 1 Supplement 1 p4299-4299, 1p
Publication Year :: 2019
Abstract: Recent prospective randomized phase III studies that include targeted agents in first-line (1L) chronic lymphocytic leukemia (CLL) all demonstrate major improvements in progression-free survival (PFS) compared to chemoimmunotherapy, with no or minimal impact on overall survival (OS). PFS has generally been a poor predictor of OS in indolent lymphoma and CLL.

Full Text Access

Tools